Sunesis Pharmaceuticals to Report Third Quarter Financial
Results on November 14, 2005
SOUTH SAN FRANCISCO, Calif., November 08, 2005 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics, today announced that Sunesis senior management will hold an investor conference call to discuss third quarter financial results on November 14, 2005 at 1:30 pm PST/4:30 pm EST.
Individual and institutional investors can access the call via 800-310-6649 (domestic) or 719-457-2693 (international). To access the live audio broadcast or the subsequent archived recording, visit the "Investors and Media -- Calendar of Events" section of the Sunesis website at sunesis.com . Please log on to Sunesis' website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.
About Sunesis Pharmaceuticals
Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit sunesis.com .
Safe Harbor Statement
This press release contains forward-looking statements that involve substantial risks and uncertainties. Sunesis may not actually achieve the plans, intentions or expectations contained in such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations contained in such forward-looking statements. Sunesis does not assume any obligation to update any such forward-looking statements.
CONTACT: investors, Eric Bjerkholt, CFO of Sunesis Pharmaceuticals, Inc.,+1-650-266-3717; or media, Karen L. Bergman, +1-650-575-1509, or MichelleCorral, +1-415-794-8662, both of BCC Partners, for Sunesis Pharmaceuticals,Inc.
Web site: sunesis.com
Ticker Symbol: (NASDAQ-NMS:SNSS)
Terms and conditions of use apply
Copyright © 2005 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
medadnews.com |
